238 related articles for article (PubMed ID: 9647611)
21. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
[TBL] [Abstract][Full Text] [Related]
22. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K
Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546
[TBL] [Abstract][Full Text] [Related]
23. [Oxaliplatin: a first DACH-platinum in oncology].
Laadem A; Cvitkovic E
Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
[TBL] [Abstract][Full Text] [Related]
24. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
Machover D; Diaz-Rubio E; de Gramont A; Schilf A; Gastiaburu JJ; Brienza S; Itzhaki M; Metzger G; N'Daw D; Vignoud J; Abad A; Francois E; Gamelin E; Marty M; Sastre J; Seitz JF; Ychou M
Ann Oncol; 1996 Jan; 7(1):95-8. PubMed ID: 9081400
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies.
Bécouarn Y; Agostini C; Trufflandier N; Boulanger V
Crit Rev Oncol Hematol; 2001 Dec; 40(3):265-72. PubMed ID: 11738949
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer.
Mitchell EP
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):30-2. PubMed ID: 11204660
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin: a new therapeutic option in colorectal cancer.
Cvitkovic E; Bekradda M
Semin Oncol; 1999 Dec; 26(6):647-62. PubMed ID: 10606258
[TBL] [Abstract][Full Text] [Related]
31. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of oxaliplatin in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):9-14. PubMed ID: 11204666
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Ducreux M; Louvet C; Bekradda M; Cvitkovic E
Semin Oncol; 1998 Apr; 25(2 Suppl 5):47-53. PubMed ID: 9609108
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin in colorectal cancer: current studies.
Goldberg R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):42-7. PubMed ID: 11204663
[TBL] [Abstract][Full Text] [Related]
35. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Wasserman E; Sutherland W; Cvitkovic E
Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
Boku N; Ohtsu A; Hyodo I; Shirao K; Miyata Y; Nakagawa K; Tamura T; Hatake K; Tanigawara Y
Jpn J Clin Oncol; 2007 Jun; 37(6):440-5. PubMed ID: 17656482
[TBL] [Abstract][Full Text] [Related]
38. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G
Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
[No Abstract] [Full Text] [Related]
40. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
